Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors to Everolimus

Next Previous
X
Search
Trial Profile

Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors to Everolimus

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Therapeutic Use

    • Most Recent Events

    • 01 Mar 2021 Planned number of patients changed from 20 to 30.
    • 03 Nov 2020 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
    • 03 Nov 2020 Planned primary completion date changed from 15 Sep 2020 to 15 Sep 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top